News

Tesetaxel is a late Phase 2 oncology oral taxane product. The data were presented at the 2010 annual meeting of the American Society of Clinical Oncology (ASCO) in

By regulation, the FDA has 60 days to conduct a filing review to determine if the application is sufficiently complete to permit a substantive review. Salix has requested

As per the terms of the agreement, Sanofi Pasteur and its affiliates acquire exclusive access to Vivalis’ platform for the discovery of fully human monoclonal antibodies targeting infectious

Atorvastatin, a cholesterol-reducing medicine is a generic equivalent of the Pfizer’s brand Lipitor, a member of the drug class known as statins. It stabilises plaque and prevents strokes

The claims covers the use of granulocyte macrophage colony stimulating factor (GM-CSF) for producing oligodendrocytes from multipotent neural stem cells in culture. This is the second patent to

Rosetta Genomics said that the ongoing study is designed to examine the ability of miRview mets to identify the primary origin of metastases in patients with cancer of

Aeterna Zentaris said that AEZS-108 is in a Phase 2 trial conducted in Europe by the German AGO Study Group (Study AGO-GYN5), in advanced ovarian and endometrial cancer,

UBMD physicians working in 18 practices will initially adopt the EHR for 35 physicians and intends to complete the deployment for all physicians within two years. Allscripts has

AMG 386 is an investigational peptibody that is designed to block angiogenesis by inhibiting angiopoietin-1 and -2 (Ang1 and Ang2). In the Amgen’s study patients were randomised to